DCN and cancer: Proteoglycans in cancer is the most enriched pathway associated with MEIS1 and HOXB13 inhibition, inducing tumor suppression and DCN, LUM, and TGFBR3, as well as regulating growth factor, migration, and invasion signaling through receptor tyrosine kinases [175].